Current concepts of the pathogenesis of the acute coronary syndromes

Circulation

Volumn 104, Issue 3, 2001, Pages 365-372

  Libby, P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Angiotensin; Atherosclerosis; Inflammation; Metalloproteinases; Myocardial infarction; Thrombosis

Indexed keywords

CATHEPSIN K; CATHEPSIN S; CYTOKINE; GAMMA INTERFERON; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE; THIOL DERIVATIVE;

CORONARY ARTERY THROMBOSIS; EXTRACELLULAR MATRIX; HEART MUSCLE ISCHEMIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THROMBOGENESIS;

EID: 0035902456     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.104.3.365     Document Type: Review

References (74)

1. The molecular bases of the acute coronary syndromes
2. Cytokines positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells
3. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization
4. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
5. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis
6. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques
7. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells
8. Cystatin C deficiency in human atherosclerosis and aortic aneurisms
9. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content
10. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
11. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells
12. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions: A structural analysis with histopathologic correlation
13. Stability and instability: The two faces of coronary atherosclerosis: The Paul Dudly White Lecture, 1995
14. Coronary plaque erosion without rupture into a lipid core: A frequent cause of coronary thrombosis in sudden coronary death
15. Evidence that tumor necrosis factor triggers apoptosis in human endothelial cells by interleukin-1-converting enzyme-like protease-dependent and -independent pathways
16. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages
17. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: Implications for tubule formation
18. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase
19. Interleukin-1 activation of vascular endothelium effects on procoagulant activity and leukocyte adhesion
20. Regulation of the fibrinolytic system of cultured human vascular endothelium by IL-1
21. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells
22. Hypercholesterolemia increases endothelial superoxide anion production
23. Nitric oxide decreases cytokine-induced endothelial activation: Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines
24. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B
25. The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis
26. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization
27. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
28. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma
29. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro
30. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice
31. Long-term effects of pravastatin on plasma concentration of C-reactive protein: The Cholesterol and Recurrent Events (CARE) Investigators
32. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)
33. Vastatins inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis
34. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
35. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
36. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study
37. Regulation of lipid and lipoprotein metabolism by PPAR activators
38. PPAR-α activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
39. PPARa activators inhibit tissue factor expression and activity in human monocytes
40. PPAR alpha agonists inhibit tissue factor expression in THP-1 cells and human monocytes
41. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells
42. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension
43. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
44. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
45. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro
46. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators
47. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells
48. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease
49. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
50. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators
51. Angiotensin induces inflammatory activation of human vascular smooth muscle cells
52. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappa B in human monocytes
53. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors
54. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells
55. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis
56. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis
57. Prothrombotic effects of angiotensin
58. Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension
59. Nitric oxide decreases cytokine-induced endothelial activation: Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines
60. Roles of infectious agents in atherosclerosis and restenosis: An assessment of the evidence and need for future research
61. Chlamydia pneumoniae IgG titres and coronary heart disease: Prospective study and meta-analysis
62. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage TNF-α and matrix metalloproteinase expression
63. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages
64. A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide
65. Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae
66. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study
67. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: Medical office assessment: Writing Group I
68. Novel inflammatory markers of coronary risk: Theory versus practice
69. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
70. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
71. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
72. Plasma concentration of soluble intercellular adhesion molecule I and risks of future myocardial infarction in apparently healthy men
73. Levels of soluble cell adhesion molecules in patients with dyslipidemia
74. Very low-density lipoprotein activates nuclear factor-kappa B in endothelial cells